Thread by @javva64

Last month the prestigious Weill Cornell Medical College published a study that compared the efficacy, durability, and breadth of coverage between an mRNA (Moderna) and an adjuvanted protein vaccine.
@DonEFord @MomNovavax #Novavax #CovidVaccines

The adjuvanted protein vaccine was not Novavax but the results were comparable to those seen by studies done with Novavax. In almost every aspect the protein vaccine was superior to the mRNA vaccine!

Study was done with groups of eight Rhesus Macaques. One group was vaccinated with Moderna mRNA vax, another with adjuvanted protein vax, and the third group was unvaccinated. The vaccinated groups were given two doses of vax. At week 52 all groups were exposed to the C-19.

Median nAb titers in the adjuvanted protein group was 44,794 at week 6, and 755 at week 52. The median nAb titers in the mRNA group was 6,430 at week 6 and 73 at week 52. After a year, the amount of nAb titers was over 10X higher in the group vaccinated with the protein vaccine!

Antibody response was also specifically measured in the nasal and salivary secretions of the vaccinated subjects. Again, the antibody levels were ten-fold higher in the adjuvanted protein group at week 52!

In addition to antibody quantity, the study also looked at the breadth of plasma antibody response to different strains of virus. The adjuvanted protein vaccine appeared to have a much better breadth of antibody response to varying strains as well.

At 52 weeks all subjects were exposed to the C-19 (Delta) virus. Viral RNA concentration was then measured over a seven-day period. It is impressive that a year after being vaccinated the virus appears to be cleared rapidly in most subjects in the protein group.

On Day 8 the subjects were euthanized, and the Lung Pathology results are shown below. All the subjects in the adjuvanted protein group appeared to have very good results, while the mRNA group appeared to have some subjects with lung inflammation and disease.

The study compared the amount of nAb with the Lung Pathology Score. The higher the quantity of nAb the better the subjects did after being exposed to the virus at week 52. At the time of exposure the antibody levels in the protein group are 10X higher than in the mRNA group!

This is just a single study, but it adds to the mountain of evidence showing the superiority of the adjuvanted protein vaccine platform. The US FDA’s slow walking of the Novavax protein vaccine makes no sense. Americans deserve this alternative!

According to Weill Cornell study the primary predictor of protection from C-19 is the nAb level in the exposed person. Here is another recent study that draws the same conclusion.
@DonEFord @MomNovavax #Novavax #Covid
docs.google.com/document/d/1Nv…

One of the arguments used for mRNA vaccines is that they generate higher T cell levels. Like the WC study this study again concludes that nAbs, not T cells, are a better predictor of protection.

"Despite reports to the contrary, T cells levels are not predictive of protection against SARS-CoV-2 infection."
"On the other hand, a strong case can be made that protection against SARS-CoV-2 infection is provided by nAbs."

"nAbs are a validated correlate of immune protection, and they have been shown in multiple studies to be predictive of vaccinal protection for both symptomatic infections and severe disease, across a range of vaccines and viral variants."

It is time the FDA considers breaking the cycle of mRNA boosters with short-lived increase in nAb levels. Allow us the strong durable antibody protection associated with adjuvanted protein vaccines. Politics should not stand in the way of approving Novavax. Do the right thing FDA